中東およびアフリカの薬物動態サービス市場予測 - 2031年まで - 地域分析 - 薬物タイプ（低分子、高分子、ワクチン）、サービスタイプ（前臨床ADMEおよびヒト研究、PK/PD分析および報告、投与シミュレーション、リスク分析など）、治療用途（腫瘍学、感染症、神経疾患、自己免疫疾患、婦人科疾患、心血管疾患、呼吸器疾患など）、エンドユーザー（製薬会社およびバイオテクノロジー会社、契約研究機関など）
慢性疾患および感染症の罹患率の上昇が中東およびアフリカの薬物動態サービス市場を後押し
糖尿病、がん、自己免疫疾患などの慢性疾患の罹患率の上昇は、世界中で医薬品開発の取り組みを促進する主な要因となっています。世界保健機関（WHO）の2024年のデータによると、世界で約4億2,200万人が糖尿病を患っており、これらの症例は主に中低所得国で見られ、毎年約150万人が死亡しています。製薬会社は、さまざまな疾患の治療薬開発の最前線に立っています。薬物動態研究は、人体内での吸収、分布、代謝、排泄 (ADME) のプロセスを分析することにより、これらの薬物が患者の体内でどのように作用するかを理解するために不可欠です。薬物が全身循環に吸収されると、薬物が作用部位 (血漿など) に到達する速度と濃度に影響します。体内での薬物の分布パターンは、薬物の生化学的特性と身体の生理機能によって異なります。代謝とは、身体による薬物の処理と、その後の化合物への変換を指します。このステップは、薬物を水溶性物質に変換して腎クリアランスに適したものにするために重要です。代謝は、コデインなどのプロドラッグを活性代謝物に変換する上でも重要です。薬物の体外排泄は主に腎臓によって制御されますが、場合によっては、薬物が肺、皮膚、または消化管から排泄されることもあります。 ADME ダイナミクスは体内の薬物のバイオアベイラビリティを定義し、薬物の維持量はクリアランス時間 (望ましい血漿濃度をバイオアベイラビリティで割った値) に基づいて計算されます。クリアランスを理解することで、医師は適切な投与速度を計算できます。
薬物動態研究は、薬物の有効性と安全性を理解するために、被験者における薬物投与レジメンの最適化に重点を置いています。これらの研究は、長期治療用に開発された薬物の安全性を確保するために不可欠であり、慢性疾患管理における薬物製剤の適合性と安定性を評価するのに役立ちます。したがって、慢性疾患と感染症の負担が増大していることから、安全で効果的な個別化治療を開発するための薬物動態研究の重要性が強調されています。
中東およびアフリカの薬物動態サービス市場の概要
南アフリカは、中東およびアフリカの薬物動態サービス市場で最大のシェアを占めています。南アフリカ政府は、投資インセンティブの提供、知的財産権（IP）の保護措置の実施、税制の簡素化、外国投資を誘致するためのより良い規制政策の導入を開始し、最終的には国内の臨床試験環境の育成を目指しています。2019年には、合計で約6,267万米ドル（10億南アフリカランド）が今後および進行中の試験に投資されました。2016年から2021年の間に、南アフリカで事業を展開する革新的な多国籍製薬企業は、国内の満たされていない医療ニーズへの対応に重点を置いた臨床研究活動を支援するために、約1億8,000万米ドル（29億5,000万南アフリカランド）を費やしました。
南アフリカはアフリカ大陸で最も経済的に発展した国であり、臨床試験に対するより優れた規制基準を確立しています。臨床研究業務のコストが低く、訴訟リスクが少ないため、南アフリカは臨床研究業務をアウトソーシングする外国企業にとって魅力的な選択肢となっています。さらに、国内の採用率が高く、規制環境が改善されているため、試験の数が増加しています。南アフリカは、革新的な製薬会社から臨床研究の実施に対して多額のスポンサーシップを受けており、減速の兆候はありません。このように、進歩的な臨床研究産業は、同国の薬物動態サービス市場の成長を後押ししています。
中東およびアフリカの薬物動態サービス市場の収益と2031年までの予測（百万米ドル）
中東およびアフリカの薬物動態サービス市場のセグメンテーション
中東およびアフリカの薬物動態サービス市場は、薬物タイプ、サービスタイプ、治療アプリケーション、エンドユーザー、および国に分類されています。
薬物タイプに基づいて、中東およびアフリカの薬物動態サービス市場は、小分子、大分子、およびワクチンにセグメント化されています。 2023年には、小分子セグメントが最大の市場シェアを占めました。
サービスタイプ別に見ると、中東およびアフリカの薬物動態サービス市場は、前臨床ADMEおよびヒト研究、PK / PD分析およびレポート、投与シミュレーション、リスク分析などに分類されています。前臨床ADMEおよびヒト研究セグメントは、2023年に最大の市場シェアを占めました。
治療用途別に見ると、中東およびアフリカの薬物動態サービス市場は、腫瘍学、感染症、神経疾患、自己免疫疾患、婦人科疾患、心血管疾患、呼吸器疾患などに分類されています。腫瘍学セグメントは、2023年に最大の市場シェアを占めました。
エンドユーザー別に見ると、中東およびアフリカの薬物動態サービス市場は、製薬およびバイオテクノロジー企業、契約研究機関などに分類されています。 2023年には、契約研究機関セグメントが最大の市場シェアを占めました。
国別に見ると、中東およびアフリカの薬物動態サービス市場は、南アフリカ、サウジアラビア、UAE、その他の中東およびアフリカに区分されています。2023年には、南アフリカが中東およびアフリカの薬物動態サービス市場シェアを独占しました。
Charles River Laboratories International Inc、Eurofins Scientific SE、Certara Inc.、Parexel International Corp、Thermo Fisher Scientific Inc.、Allucent、PACIFIC BIOLABS、SGS SAは、中東およびアフリカの薬物動態サービス市場で事業を展開している大手企業です。
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Middle East & Africa Pharmacokinetics Services Market - Key Market Dynamics
4.1 Market Drivers
4.1.1 Rising Prevalence of Chronic and Infectious Diseases
4.1.2 Expanding Range of Application of Pharmacokinetic Studies
4.1.3 Outsourcing of Pharmacokinetics Services to CROs
4.2 Market Restraints
4.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
4.3 Market Opportunities
4.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
4.4 Future Trend
4.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
4.5 Impact of Drivers and Restraints:
5. Pharmacokinetics Services Market - Middle East & Africa Analysis
5.1 Middle East & Africa Pharmacokinetics Services Market Overview
5.2 Middle East & Africa Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
6. Middle East & Africa Pharmacokinetics Services Market Analysis - by Drug Type
6.1 Overview
6.2 Small Molecule
6.2.1 Overview
6.2.2 Small Molecule: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
6.3 Large Molecule
6.3.1 Overview
6.3.2 Large Molecule: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
6.4 Vaccines
6.4.1 Overview
6.4.2 Vaccines: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7. Middle East & Africa Pharmacokinetics Services Market Analysis - by Service Type
7.1 Overview
7.2 Pre-Clinical ADME and Human Studies
7.2.1 Overview
7.2.2 Pre-Clinical ADME and Human Studies: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.3 PK/PD Analysis and Reporting
7.3.1 Overview
7.3.2 PK/PD Analysis and Reporting: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Dosing Simulations
7.4.1 Overview
7.4.2 Dosing Simulations: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Risk Analysis
7.5.1 Overview
7.5.2 Risk Analysis: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8. Middle East & Africa Pharmacokinetics Services Market Analysis - by Therapeutic Application
8.1 Oncology
8.1.1 Overview
8.1.2 Oncology: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Infectious Diseases
8.2.1 Overview
8.2.2 Infectious Diseases: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Neurological Disorders
8.3.1 Overview
8.3.2 Neurological Disorders: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Autoimmune Diseases
8.4.1 Overview
8.4.2 Autoimmune Diseases: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Gynecological Disorders
8.5.1 Overview
8.5.2 Gynecological Disorders: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Cardiovascular Diseases
8.6.1 Overview
8.6.2 Cardiovascular Diseases: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.7 Respiratory Disorders
8.7.1 Overview
8.7.2 Respiratory Disorders: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9. Middle East & Africa Pharmacokinetics Services Market Analysis - by End User
9.1 Pharmaceutical and Biotechnology Companies
9.1.1 Overview
9.1.2 Pharmaceutical and Biotechnology Companies: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Contract Research Organization
9.2.1 Overview
9.2.2 Contract Research Organization: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Others
9.3.1 Overview
9.3.2 Others: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10. Middle East & Africa Pharmacokinetics Services Market - Country Analysis
10.1 Middle East and Africa
10.1.1 Middle East & Africa Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
10.1.1.1 Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.1.1 Overview
10.1.1.1.2 Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.1.3 Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.1.4 Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.1.5 Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.1.6 Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market Breakdown, by End User
10.1.1.2 South Africa: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 South Africa: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.2.3 South Africa: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.2.4 South Africa: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.2.5 South Africa: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.2.6 South Africa: Middle East & Africa Pharmacokinetics Services Market Breakdown, by End User
10.1.1.3 United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.3.3 United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.3.4 United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.3.5 United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.3.6 United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market Breakdown, by End User
10.1.1.4 Rest of Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.4.1 Overview
10.1.1.4.2 Rest of Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.4.3 Rest of Middle East & Africa Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.4.4 Rest of Middle East & Africa Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.4.5 Rest of Middle East & Africa Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.4.6 Rest of Middle East & Africa Pharmacokinetics Services Market Breakdown, by End User
11. Company Profile
11.1 Charles River Laboratories International Inc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Eurofins Scientific SE
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Certara Inc.
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.4 Parexel International Corp
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Thermo Fisher Scientific Inc.
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Allucent
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 PACIFIC BIOLABS
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 SGS SA
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Glossary of Terms for Pharmacokinetic Services Market
?
List of Tables
Table 1. Middle East & Africa Pharmacokinetics Services Market Segmentation
Table 2. Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Drug Type
Table 3. Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Service Type
Table 4. Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Therapeutic Application
Table 5. Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by End User
Table 6. South Africa: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Drug Type
Table 7. South Africa: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Service Type
Table 8. South Africa: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Therapeutic Application
Table 9. South Africa: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by End User
Table 10. United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Drug Type
Table 11. United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Service Type
Table 12. United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Therapeutic Application
Table 13. United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by End User
Table 14. Rest of Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Drug Type
Table 15. Rest of Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Service Type
Table 16. Rest of Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Therapeutic Application
Table 17. Rest of Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by End User
Table 18. Glossary of Terms
?
List of Figures
Figure 1. Middle East & Africa Pharmacokinetics Services Market Segmentation, by Country
Figure 2. Middle East & Africa Pharmacokinetics Services Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Middle East & Africa Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
Figure 5. Middle East & Africa Pharmacokinetics Services Market Share (%) - by Drug Type (2023 and 2031)
Figure 6. Small Molecule: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 7. Large Molecule: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 8. Vaccines: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 9. Middle East & Africa Pharmacokinetics Services Market Share (%) - by Service Type (2023 and 2031)
Figure 10. Pre-Clinical ADME and Human Studies: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 11. PK/PD Analysis and Reporting: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 12. Dosing Simulations: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 13. Risk Analysis: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 14. Others: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 15. Middle East & Africa Pharmacokinetics Services Market Share (%) - by Therapeutic Application (2023 and 2031)
Figure 16. Oncology: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 17. Infectious Diseases: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 18. Neurological Disorders: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 19. Autoimmune Diseases: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 20. Gynecological Disorders: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 21. Cardiovascular Diseases: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 22. Respiratory Disorders: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 23. Others: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 24. Middle East & Africa Pharmacokinetics Services Market Share (%) - by End User (2023 and 2031)
Figure 25. Pharmaceutical and Biotechnology Companies: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 26. Contract Research Organization: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 27. Others: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 28. Middle East & Africa Pharmacokinetics Services Market by Key Countries - Revenue 2023 (US$ Million)
Figure 29. Middle East & Africa Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 30. Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million)
Figure 31. South Africa: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million)
Figure 32. United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million)
Figure 33. Rest of Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million)
- Allucent
- Certara Inc.
- Charles River Laboratories International Inc
- Eurofins Scientific SE
- PACIFIC BIOLABS
- Parexel International Corp
- SGS SA
- Thermo Fisher Scientific Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa pharmacokinetics services market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa pharmacokinetics services market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Middle East & Africa pharmacokinetics services market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.